BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yin H, Jiang N, Shi W, Chi X, Liu S, Chen JL, Wang S. Development and Effects of Influenza Antiviral Drugs. Molecules 2021;26:810. [PMID: 33557246 DOI: 10.3390/molecules26040810] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Gunther RC, Bharathi V, Miles SD, Tumey LR, Schmedes CM, Tatsumi K, Bridges MD, Martinez D, Montgomery SA, Beck MA, Camerer E, Mackman N, Antoniak S. Myeloid Protease-Activated Receptor-2 Contributes to Influenza A Virus Pathology in Mice. Front Immunol 2021;12:791017. [DOI: 10.3389/fimmu.2021.791017] [Reference Citation Analysis]
2 Ouchi D, García-Sangenís A, Moragas A, van der Velden AW, Verheij TJ, Butler CC, Bongard E, Coenen S, Cook J, Francis NA, Godycki-Cwirko M, Lundgren PT, Lionis C, Radzeviciene Jurgute R, Chlabicz S, De Sutter A, Bucher HC, Seifert B, Kovács B, de Paor M, Sundvall PD, Aabenhus R, Harbin NJ, Ieven G, Goossens H, Lindbæk M, Bjerrum L, Llor C. Clinical prediction of laboratory-confirmed influenza in adults with influenza-like illness in primary care. A randomized controlled trial secondary analysis in 15 European countries. Fam Pract 2021:cmab122. [PMID: 34611715 DOI: 10.1093/fampra/cmab122] [Reference Citation Analysis]
3 Kálai T, Pongrácz JE, Mátyus P. Recent Advances in Influenza, HIV and SARS-CoV-2 Infection Prevention and Drug Treatment—The Need for Precision Medicine. Chemistry 2022;4:216-58. [DOI: 10.3390/chemistry4020019] [Reference Citation Analysis]
4 Świerczyńska M, Mirowska-Guzel DM, Pindelska E. Antiviral Drugs in Influenza. Int J Environ Res Public Health 2022;19:3018. [PMID: 35270708 DOI: 10.3390/ijerph19053018] [Reference Citation Analysis]
5 Hossain MG, Akter S, Dhole P, Saha S, Kazi T, Majbauddin A, Islam MS. Analysis of the Genetic Diversity Associated With the Drug Resistance and Pathogenicity of Influenza A Virus Isolated in Bangladesh From 2002 to 2019. Front Microbiol 2021;12:735305. [PMID: 34603265 DOI: 10.3389/fmicb.2021.735305] [Reference Citation Analysis]
6 Ashooriha M, Ahmadi R, Ahadi H, Emami S. Application of kojic acid scaffold in the design of non-tyrosinase enzyme inhibitors. Chem Biol Drug Des 2022. [PMID: 35555863 DOI: 10.1111/cbdd.14065] [Reference Citation Analysis]
7 He J, Huang H, Li B, Li H, Zhao Y, Li Y, Ye W, Qi W, Tang W, Wang L. Identification of cytochrome c oxidase subunit 4 isoform 1 as a positive regulator of influenza virus replication. Front Microbiol 2022;13:862205. [DOI: 10.3389/fmicb.2022.862205] [Reference Citation Analysis]
8 Lu Y, Wang Y, Shen C, Luo J, Yu W. Decreased Incidence of Influenza During the COVID-19 Pandemic. IJGM 2022;Volume 15:2957-62. [DOI: 10.2147/ijgm.s343940] [Reference Citation Analysis]